Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Sorting nexin 10 sustains PDGF receptor signaling in glioblastoma stem cells via endosomal protein sorting
Ryan C. Gimple, … , Sameer Agnihotri, Jeremy N. Rich
Ryan C. Gimple, … , Sameer Agnihotri, Jeremy N. Rich
Published February 16, 2023
Citation Information: JCI Insight. 2023;8(6):e158077. https://doi.org/10.1172/jci.insight.158077.
View: Text | PDF
Research Article Oncology Stem cells

Sorting nexin 10 sustains PDGF receptor signaling in glioblastoma stem cells via endosomal protein sorting

  • Text
  • PDF
Abstract

Glioblastoma is the most malignant primary brain tumor, the prognosis of which remains dismal even with aggressive surgical, medical, and radiation therapies. Glioblastoma stem cells (GSCs) promote therapeutic resistance and cellular heterogeneity due to their self-renewal properties and capacity for plasticity. To understand the molecular processes essential for maintaining GSCs, we performed an integrative analysis comparing active enhancer landscapes, transcriptional profiles, and functional genomics profiles of GSCs and non-neoplastic neural stem cells (NSCs). We identified sorting nexin 10 (SNX10), an endosomal protein sorting factor, as selectively expressed in GSCs compared with NSCs and essential for GSC survival. Targeting SNX10 impaired GSC viability and proliferation, induced apoptosis, and reduced self-renewal capacity. Mechanistically, GSCs utilized endosomal protein sorting to promote platelet-derived growth factor receptor β (PDGFRβ) proliferative and stem cell signaling pathways through posttranscriptional regulation of the PDGFR tyrosine kinase. Targeting SNX10 expression extended survival of orthotopic xenograft–bearing mice, and high SNX10 expression correlated with poor glioblastoma patient prognosis, suggesting its potential clinical importance. Thus, our study reveals an essential connection between endosomal protein sorting and oncogenic receptor tyrosine kinase signaling and suggests that targeting endosomal sorting may represent a promising therapeutic approach for glioblastoma treatment.

Authors

Ryan C. Gimple, Guoxin Zhang, Shuai Wang, Tengfei Huang, Jina Lee, Suchet Taori, Deguan Lv, Deobrat Dixit, Matthew E. Halbert, Andrew R. Morton, Reilly L. Kidwell, Zhen Dong, Briana C. Prager, Leo J.Y. Kim, Zhixin Qiu, Linjie Zhao, Qi Xie, Qiulian Wu, Sameer Agnihotri, Jeremy N. Rich

×

Figure 11

SNX10 maintains PDGFRβ protein stability via a posttranscriptional mechanism and alters sensitivity to multitargeted kinase inhibitors.

Options: View larger image (or click on image) Download as PowerPoint
SNX10 maintains PDGFRβ protein stability via a posttranscriptional mecha...
(A) qPCR analysis of PDGFA–D mRNA expression in 2 GSCs after SNX10 knockdown. mRNA expression was normalized to actin. (B) qPCR analysis of PDGFRβ mRNA expression in 3 GSCs after SNX10 knockdown. mRNA expression was normalized to actin. (C) Western blot showing protein levels of PDGFRβ in GSC 3565 following transduction with 1 of 2 shRNAs targeting SNX10 or a nontargeting shRNA (shCONT) over a 12-hour time course following treatment with cycloheximide (10 μg/mL). Samples were run in a single gel, with entire gels shown in the supplemental material. (D) Quantification of PDGFRβ density (relative to tubulin) showing protein degradation rate of PDGFRβ in GSC 3565 following transduction with 1 of 2 shRNAs targeting SNX10 or shCONT. (E) Western blot showing protein levels of PDGFRβ and ubiquitin in PDGFRβ IP group or cell lysates following transduction with 1 of 2 shRNAs targeting SNX10 or shCONT following treatment with MG132. Samples were run in a single gel with entire gels shown in the supplemental material. (F and G) Normalized cell viability of (F) GSC CW468 and (G) GSC 3565 following transduction with shRNAs targeting PDGFRβ compared to shCONT over a 6-day time course. n = 3. Significance was determined by 2-way ANOVA with Tukey’s multiple-comparison test. (H) Normalized cell viability of GSC 3565 following transduction with shRNA targeting SNX10 with or without PDGFRβ overexpression compared to shCONT over a 6-day time course. n = 3. Significance was determined by 2-way ANOVA with Tukey’s multiple-comparison test. (I) Limiting dilution assay (LDA) in GSC 3565 following transduction with an shRNA construct targeting SNX10 with or without PDGFRβ overexpression compared to shCONT. (J and K) Normalized cell viability of GSC 23 following transduction with shRNAs targeting SNX10 compared to shCONT over varying concentrations of (J) lenvatinib or (K) pazopanib. Data are presented as mean ± SD. Significance was determined by 1-way ANOVA with Tukey’s multiple-comparison test (A and B) or 2-way ANOVA with Tukey’s multiple-comparison test (G and H). Significance in I was determined using extreme limiting dilution assays as described in Hu and Smyth (79). **P < 0.01; ***P < 0.001. NS, not significant.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts